Humacyte, Inc. (HUMA) recently closed at $1.79, gaining 1.7% on a day the S&P 500 declined, and has risen 15.03% over the past month, significantly outperforming both the broader market and the Medical sector. The company's upcoming quarterly EPS is projected at -$0.17, a 48.48% year-over-year improvement, with full-year estimates at -$0.35 EPS (up 66.67% YoY) and $3.51 million in revenue. Despite these projected improvements, the Zacks Consensus EPS estimate has remained stagnant over the past month, and HUMA currently holds a Zacks Rank of #3 (Hold).
Humacyte, Inc. (HUMA) demonstrated notable outperformance, closing up 1.7% on a day when the S&P 500 declined by 0.16% and the Nasdaq fell by 0.76%. Over the past month, HUMA shares have surged 15.03%, significantly outpacing the Medical sector's 1.54% gain and the S&P 500's 1.14% increase, indicating strong recent momentum relative to broader market and sector trends. The company's upcoming quarterly EPS is projected at -$0.17, representing a substantial 48.48% improvement year-over-year. For the full fiscal year, Zacks Consensus Estimates forecast an EPS of -$0.35, a 66.67% improvement from the prior year, alongside a revenue projection of $3.51 million, which indicates flat year-over-year growth. Despite the projected EPS improvements, the Zacks Consensus EPS estimate for HUMA has remained stagnant over the past month, and the stock currently holds a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry, to which Humacyte belongs, is ranked 94, placing it in the top 39% of over 250 industries, suggesting a favorable industry backdrop that could provide some support.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
